| Carcinoma in situ of bladder
Adstiladrin vs Valstar
Side-by-side clinical, coverage, and cost comparison for carcinoma in situ of bladder.Deep comparison between: Adstiladrin vs Valstar with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsValstar has a higher rate of injection site reactions vs Adstiladrin based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Valstar but not Adstiladrin, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Adstiladrin
Valstar
At A Glance
Intravesical instillation
Every 3 months
IFN-alpha2b gene therapy
Intravesical instillation
Once weekly for 6 weeks
Anthracycline topoisomerase II inhibitor
Indications
- Carcinoma in situ of bladder
- Carcinoma in situ of bladder
Dosing
Carcinoma in situ of bladder 75 mL at a concentration of 3 x 10^11 vp/mL instilled intravesically once every 3 months via urinary catheter, retained in the bladder for 1 hour; premedication with an anticholinergic is recommended before each instillation.
Carcinoma in situ of bladder 800 mg administered intravesically once weekly for six weeks; delay administration at least two weeks after transurethral resection and/or fulguration.
Contraindications
- Prior hypersensitivity reactions to interferon alfa or to any component of the product
- Perforated bladder
- Known hypersensitivity to anthracyclines or polyoxyl castor oil
- Active urinary tract infection
- Small bladder capacity and unable to tolerate a 75 mL instillation
Adverse Reactions
Most common (>10%) Instillation site discharge, fatigue, pyrexia, chills, bladder spasm, micturition urgency, hematuria, dysuria; laboratory abnormalities (>15%): glucose increased, triglycerides increased, creatinine increased, phosphate decreased, hemoglobin decreased
Serious Coronary artery disease, hematuria
Most common local Urinary frequency, dysuria, urinary urgency, bladder spasm, hematuria, bladder pain, urinary incontinence, cystitis, nocturia, local burning symptoms, urethral pain, pelvic pain
Most common systemic (>=1%) Urinary tract infection, abdominal pain, nausea, asthenia, headache, malaise, urinary retention, dizziness, back pain, rash, diarrhea, anemia, vomiting, chest pain, fever, vasodilation, hyperglycemia, peripheral edema, myalgia, pneumonia
Pharmacology
Non-replicating adenoviral vector-based gene therapy that delivers a transgene encoding human interferon alfa-2b (IFN-alpha2b) to bladder urothelium, resulting in transient local IFN-alpha2b expression with anticipated anti-tumor effects.
Valrubicin is a semisynthetic anthracycline that inhibits DNA topoisomerase II, arrests the cell cycle in G2, and inhibits nucleoside incorporation into nucleic acids, resulting in chromosomal damage and cytotoxicity in bladder cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Adstiladrin
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (0/12)
Valstar
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Adstiladrin
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Valstar
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Adstiladrin
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Valstar
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$100
Adstiladrin Copay ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Bladder Cancer (Federal Healthcare Program): Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AdstiladrinView full Adstiladrin profile
ValstarView full Valstar profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.